Doctor Reveals the Best Peptide Stack for Weight Loss in 2026

Summary

Dr. Jones presents a weight-loss peptide framework based on choosing interventions for a person’s current needs—not simply seeking the “strongest” peptide. His central idea is to address three systems in order: appetite control, fat mobilization, and metabolic enhancement. He also stresses protecting muscle during weight loss.

The three-stage framework

1. Control appetite first. The speaker says that if appetite and food-related thoughts remain difficult to manage, addressing fat mobilization or metabolism may not help. He discusses GLP-1 medications and mentions tesofensine as an oral option for some people who cannot use or tolerate GLP-1s.
2. Address fat mobilization next. He describes AOD-9604 as a compound intended to help release stored fat for use as energy, rather than directly “burning” fat. He discusses pairing it with fasting, particularly for people he says may have insulin resistance, PCOS, or menopause-related challenges.
3. Consider metabolic enhancement according to the person’s phase.
   • For a “reset” phase after prolonged calorie restriction, low energy, or a weight-loss plateau, he discusses SLU-PP-332.
   • For a “healthy” phase—when energy and eating have stabilized—he discusses O304 or MIC as possible metabolic-enhancement options.
   • His key timing advice is not to use an enhancement approach while someone is still trying to recover from prolonged restriction.

Muscle preservation and supportive habits

• Prioritize adequate protein. The speaker says protein intake is foundational for preserving muscle during weight loss and cites roughly one gram per pound of target body weight as the amount used in his clinic.
• Include resistance training. He notes that muscle loss can vary with protein intake, protocol, and resistance training.
• Consider muscle-preservation strategies only with clinical guidance. He discusses CJC-1295 without DAC paired with ipamorelin, and also mentions tesamorelin. He presents these as options that may support growth-hormone release and recovery, but not as substitutes for protein and lifestyle habits.

Mistakes he says to avoid

• Adding a fat-mobilization approach before appetite is under control.
• Using a metabolic-enhancement compound during a period of severe restriction or low energy, rather than after recovery.
• Choosing compounds based on online trends or perceived strength without identifying the person’s main difficulty.

Important context

These are the presenter’s claims and recommendations, not established individualized medical advice. The subtitles themselves note that evidence for some compounds is limited: for example, the speaker says SLU-PP-332 is supported mainly by animal research and acknowledges that AOD-9604 lacks large human randomized trials. Peptides, fasting, and prescription medications can carry risks; anyone considering them should consult a qualified healthcare professional rather than self-prescribing or following an online “stack.”

Presenter/source: Dr. Jones, DC. He also refers generally to research studies, his clinic’s experience, and patient reports; no specific studies or additional named sources are identified.